Precision Neuroscience Partners with SCI Ventures to Advance Brain-Computer Interface Technology

Precision Neuroscience, a medical technology company developing advanced brain-computer interface (BCI) systems, has announced a strategic partnership with SCI Ventures, a venture fund backed by major spinal cord injury organizations. This collaboration marks a significant step forward in the development of innovative solutions for individuals with paralysis and neurological disorders.

Groundbreaking BCI Technology

Precision Neuroscience's flagship product, the Layer 7 cortical interface, is at the forefront of BCI technology. This remarkable device is a flexible film strip, merely one-fifth the thickness of a human hair, that houses 1,024 electrodes within an area comparable to a postage stamp. Designed to sit on the brain's surface, the Layer 7 interface can record high-resolution brain signals and convert them into digital commands, potentially allowing patients to operate computers, communicate, and control external devices using only their thoughts.

The Layer 7 device offers a unique balance between functionality and minimal invasiveness. It can be inserted and removed through a submillimeter incision in the skull without causing damage to healthy tissue. This approach addresses a critical concern in the BCI field, as it provides a high level of functionality without requiring deeply invasive brain surgery.

Strategic Partnership and Investment

The partnership between Precision Neuroscience and SCI Ventures brings together cutting-edge technology and a vast network of resources in the spinal cord injury community. While the exact financial terms were not disclosed, SCI Ventures has made a "seven-figure" investment in Precision Neuroscience, according to Adrien Cohen, SCI's founding Managing Director.

This collaboration grants Precision Neuroscience access to SCI's extensive network of patients, doctors, and regulatory experts. This valuable resource is expected to accelerate the company's efforts to bring its device to patients suffering from spinal cord injuries, ALS, stroke, and other neurological conditions.

Clinical Progress and Regulatory Milestones

Precision Neuroscience has made significant strides in the clinical development of its Layer 7 device. In April, the company received FDA clearance for temporary use of the device for up to 30 days. To date, the Layer 7 interface has been tested in 58 patients, primarily in surgical settings. These trials are part of Precision's ongoing efforts to gather data in support of FDA approval for a long-term BCI system.

The partnership with SCI Ventures is expected to play a crucial role in Precision's path to commercialization. John Woock, Ph.D., Precision's Chief Business Officer, emphasized the importance of incorporating patient feedback into clinical studies and the final product design. This user-centric approach aims to ensure that the technology can be seamlessly integrated into patients' daily lives.